In patients with hormone receptor (HR)-positive, locally advanced or metastatic breast cancer, treatment with fulvestrant (Faslodex) demonstrated superiority over anastrozole (Arimidex) in achieving extended progression-free survival, according to a recent press release from AstraZeneca.

Read More ›

For protection against breast cancer recurrence, results from one recently reported study can best be described as “good news, bad news.”

Read More ›

A steroid mouthwash can reduce the incidence of stomatitis associated with the use of everoli­mus. Data from the first prospective trial of prophylactic use of a steroid mouth rinse demonstrated a 26% incidence of stomatitis among patients with metastatic breast cancer who used the mouth rinse versus 67% in historical controls. Read More ›

San Antonio, TX–A scalp cooling system protects against chemotherapy-induced hair loss in patients with breast cancer, and contributes to their well-being. The effects of the DigniCap scalp cooling system in 110 patients were presented at the 2015 San Antonio Breast Cancer Symposium. Read More ›

Patients with early breast cancer and a low Oncotype DX Recurrence Score (RS) can be safely treated with hormone therapy alone and avoid chemotherapy, according to results of the National Cancer Institute–sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial. Read More ›

In patients receiving everolimus in clinical trials, stomatitis frequently occurred in the initial weeks of treatment, but this did not compromise clinical outcomes, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. Read More ›

A small study indicates that many patients with breast cancer are not informed about lymphedema as a possible treatment-related side effect and do not know how to recognize its symptoms. Read More ›

In breast cancer patients with bone metastasis, less frequent infusion of zoledronic acid was as effective as the standard monthly dose, the randomized OPTIMIZE-2 study showed. Read More ›

Of all newly diagnosed breast cancer, 6% to 10% is metastatic, and a proportion of women with early breast cancer eventually develop metastasis. Treatment of metastatic breast cancer has improved considerably, and patients are living longer with metastatic disease. Read More ›

Advances in breast cancer diagnostics and treatment have led to improved survival for patients with breast cancer. However, survivors still face psychosocial and physical challenges. Read More ›